Jaguar Health, Inc. (JAGX) financial statements (2021 and earlier)
Company profile
| Business Address |
200 PINE STREET SUITE 400 SAN FRANCISCO, CA 94104 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 8 | 3 | 3 | 1 | 1 | 8 | ||
| Cash and cash equivalents | 8 | 3 | 3 | 1 | 1 | 8 | ||
| Restricted cash and investments | 0 | 0 | 1 | |||||
| Receivables | 5 | 2 | 1 | 0 | 0 | 0 | ||
| Inventory, net of allowances, customer advances and progress billings | 3 | 2 | 3 | 2 | 0 | 0 | ||
| Inventory | 3 | 2 | 3 | 2 | 0 | 0 | ||
| Prepaid expense | 0 | 0 | ||||||
| Deferred costs | 0 | 0 | ||||||
| Other undisclosed current assets | 2 | 2 | 1 | 0 | ||||
| Total current assets: | 18 | 10 | 8 | 4 | 3 | 8 | ||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Intangible assets, net (including goodwill) | 24 | 26 | 32 | 39 | ||||
| Goodwill | 5 | |||||||
| Intangible assets, net (excluding goodwill) | 24 | 26 | 32 | 33 | ||||
| Restricted cash and investments | 3 | |||||||
| Other undisclosed noncurrent assets | 0 | 0 | 0 | 0 | 0 | |||
| Total noncurrent assets: | 25 | 27 | 33 | 40 | 1 | 4 | ||
| TOTAL ASSETS: | 43 | 36 | 41 | 44 | 4 | 12 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 9 | 8 | 10 | 10 | 1 | 1 | ||
| Accounts payable | 5 | 5 | 5 | 7 | 1 | 1 | ||
| Accrued liabilities | 4 | 3 | 5 | 2 | 1 | 1 | ||
| Debt | 4 | 7 | 5 | 2 | 2 | 2 | ||
| Deferred compensation liability | 0 | |||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 0 | 0 | 0 | ||
| Other undisclosed current liabilities | 0 | 0 | 11 | 4 | 1 | 1 | ||
| Total current liabilities: | 13 | 15 | 27 | 15 | 4 | 4 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 12 | 0 | 11 | 2 | 4 | |||
| Long-term debt, excluding current maturities | 12 | 0 | 11 | 2 | 4 | |||
| Liabilities, other than long-term debt | 0 | 0 | ||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 0 | 0 | |||
| Total noncurrent liabilities: | 12 | 0 | 11 | 2 | 4 | |||
| Total liabilities: | 26 | 16 | 27 | 26 | 6 | 8 | ||
| Temporary equity, carrying amount | 9 | |||||||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | 17 | 11 | 5 | 17 | (2) | 4 | ||
| Common stock | 0 | 0 | ||||||
| Additional paid in capital | 184 | 142 | 100 | 80 | 38 | 30 | ||
| Accumulated deficit | (167) | (133) | (95) | (62) | (40) | (26) | ||
| Warrants and rights outstanding | 0 | |||||||
| Other undisclosed stockholders' equity attributable to parent | 0 | 2 | 0 | 0 | ||||
| Other undisclosed stockholders' equity | 10 | |||||||
| Total stockholders' equity: | 17 | 21 | 5 | 17 | (2) | 4 | ||
| TOTAL LIABILITIES AND EQUITY: | 43 | 36 | 41 | 44 | 4 | 12 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 9 | 6 | 4 | 4 | 0 | 0 | |
| Revenue, net | ✕ | ✕ | ✕ | 1 | 0 | 0 | |
| Cost of revenue | (3) | (4) | (3) | (1) | (0) | (0) | |
| Gross profit: | 6 | 2 | 2 | 3 | 0 | 0 | |
| Operating expenses | (27) | (30) | (35) | (39) | (14) | (13) | |
| Other undisclosed operating income (loss) | (5) | (1) | 3 | 1 | 0 | 0 | |
| Operating loss: | (27) | (29) | (31) | (34) | (14) | (12) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 0 | 0 | 0 | 0 | (0) | (0) | |
| Interest and debt expense | (5) | (11) | (3) | (2) | (1) | (3) | |
| Loss from continuing operations before equity method investments, income taxes: | (31) | (40) | (34) | (36) | (15) | (16) | |
| Other undisclosed income (loss) from continuing operations before income taxes | (3) | 1 | 2 | 1 | |||
| Loss from continuing operations before income taxes: | (34) | (39) | (32) | (35) | (15) | (16) | |
| Income tax expense (benefit) | (0) | 13 | (6) | (5) | |||
| Loss before gain (loss) on sale of properties: | (34) | (39) | (32) | (22) | (20) | (21) | |
| Other undisclosed net income | 6 | 4 | |||||
| Net loss attributable to parent: | (34) | (39) | (32) | (22) | (15) | (16) | |
| Preferred stock dividends and other adjustments | (1) | (0) | |||||
| Other undisclosed net income available to common stockholders, basic | 1 | ||||||
| Net loss available to common stockholders, diluted: | (34) | (39) | (32) | (22) | (15) | (17) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (34) | (39) | (32) | (22) | (15) | (16) | |
| Comprehensive loss, net of tax, attributable to parent: | (34) | (39) | (32) | (22) | (15) | (16) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.